Factors Affecting Patient Selection for Prostate Brachytherapy: What Nurses Should Know

Debra Zeroski, RN, OCN®, Laurie Abel, RN, BSN, OCN®, Wayne M. Butler, PhD, Kent Wallner, MD, and Gregory S. Merrick, MD

Prostate brachytherapy is a proven treatment for clinically localized prostate cancer; however, many clinicians have multiple misconceptions regarding patient selection criteria. Although most patients are candidates for the procedure, contraindications do exist. This article examines criteria for patient selection and the need for adjuvant therapies, proposes management philosophies, and discusses the impact of each on treatment decisions. Nurses’ role in the decision-making process and how they can facilitate patients and families in making informed choices also are discussed. Clinical studies seek to further define patient selection criteria and examine optimal choices for adjuvant treatment and isotope preference. Expanding the knowledge base of nurses helps enhance patient care.

Prostate brachytherapy is determined via transrectal ultrasound, which visualizes and measures the prostate gland. The technical difficulty of seeding a large-volume prostate puts patients at higher risk for acute and long-term urinary difficulties. Before brachytherapy can be considered, patients with large-volume prostates are offered androgen deprivation therapy to shrink the prostate. This cytoreduction usually takes three months and allows for an overall improved implant. Patients who present with small-volume prostate glands (i.e., < 20 cm³) have shown no difference in urinary morbidity in several studies (Merrick, Butler, Dorsey, & Lief, 2001; Merrick, Butler, Lief, & Dorsey, 2000; Merrick, Butler, Wallner, Galbreath, & Lief, 2003). In addition, studies have shown that patients with larger prostate glands can be implanted safely without subsequently experiencing an overabundance of urinary dysfunction (Merrick et al., 2000; Merrick, Butler, Wallner, Galbreath, et al., 2003).

Submitted July 2004. Accepted for publication February 21, 2005. (Mention of specific products and opinions related to those products do not indicate or imply endorsement by the Clinical Journal of Oncology Nursing or the Oncology Nursing Society.)

Digital Object Identifier: 10.1188/05.CJON.553-560

Prostate Factors

Size

Traditionally, patients with large prostates (i.e., volume > 50 cm³) have not been considered to be candidates for prostate brachytherapy because of the possibility of increased postoperative urinary symptoms, such as urinary retention, dysuria, and urgency. These complications are caused by the higher number of seeds required to be inserted into a larger prostate. Prostate size is determined via transrectal ultrasound, which visualizes and measures the prostate gland. The technical difficulty of seeding a large-volume prostate puts patients at higher risk for acute and long-term urinary difficulties. Before brachytherapy can be considered, patients with large-volume prostates are offered androgen deprivation therapy to shrink the prostate. This cytoreduction usually takes three months and allows for an overall improved implant. Patients who present with small-volume prostate glands (i.e., < 20 cm³) have shown no difference in urinary morbidity in several studies (Merrick, Butler, Dorsey, & Lief, 2001; Merrick, Butler, Lief, & Dorsey, 2000; Merrick, Butler, Wallner, Galbreath, & Lief, 2003). In addition, studies have shown that patients with larger prostate glands can be implanted safely without subsequently experiencing an overabundance of urinary dysfunction (Merrick et al., 2000; Merrick, Butler, Wallner, Galbreath, et al., 2003).

Submitted July 2004. Accepted for publication February 21, 2005. (Mention of specific products and opinions related to those products do not indicate or imply endorsement by the Clinical Journal of Oncology Nursing or the Oncology Nursing Society.)

Digital Object Identifier: 10.1188/05.CJON.553-560

Prostate Factors

Size

Traditionally, patients with large prostates (i.e., volume > 50 cm³) have not been considered to be candidates for prostate brachytherapy because of the possibility of increased postoperative urinary symptoms, such as urinary retention, dysuria, and urgency. These complications are caused by the higher number of seeds required to be inserted into a larger prostate. Prostate size is determined via transrectal ultrasound, which visualizes and measures the prostate gland. The technical difficulty of seeding a large-volume prostate puts patients at higher risk for acute and long-term urinary difficulties. Before brachytherapy can be considered, patients with large-volume prostates are offered androgen deprivation therapy to shrink the prostate. This cytoreduction usually takes three months and allows for an overall improved implant. Patients who present with small-volume prostate glands (i.e., < 20 cm³) have shown no difference in urinary morbidity in several studies (Merrick, Butler, Dorsey, & Lief, 2001; Merrick, Butler, Lief, & Dorsey, 2000; Merrick, Butler, Wallner, Galbreath, & Lief, 2003). In addition, studies have shown that patients with larger prostate glands can be implanted safely without subsequently experiencing an overabundance of urinary dysfunction (Merrick et al., 2000; Merrick, Butler, Wallner, Galbreath, et al., 2003).

Submitted July 2004. Accepted for publication February 21, 2005. (Mention of specific products and opinions related to those products do not indicate or imply endorsement by the Clinical Journal of Oncology Nursing or the Oncology Nursing Society.)

Digital Object Identifier: 10.1188/05.CJON.553-560